



422-A216

Solvent-free poly(lactide)-based drug delivery system

Invention

Most poly(lactide)-based drug delivery systems need to be formulated with an organic solvent and administered as solutions or in form of nano- and micro-particles.

Researchers at the University of Geneva have developed novel alkyl-substituted poly(lactides) that are viscous and can be injected without the use of a solvent and without forming nano- or micro-particles prior to injection. The final drug product is simply produced by mixing.

Applications

The material is suitable for improved incorporation and controlled long-term delivery of hydrophobic compounds.

Therapeutic areas include: long-term cancer treatment, rheumatoid arthritis, intra-joint, intraocular and peridental treatments

Advantages

- No solvents required
- No need to form nano- or micro-particles
- Viscous - can be simply mixed with a hydrophobic drug
- More hydrophobic than currently used PLA-based drug delivery systems
- Improved release profile of hydrophobic compounds
- Protection of the compound against degradation

Status

PCT patent application, nationalized in US, CA, EP and JP, priority date 22 April 2008

In Q2 2008, we have established an alliance with a major drug-delivery company, under which our partner will be available to manufacture the polymers, and develop and clinically test formulations based on this technology platform.

Type of partnership sought

Prof. Gurny is available to collaborate with pharmaceutical companies to explore feasibility of developing formulations of specific compounds based on this technology platform



Contact